joshua richter, md, on the phase 3 icaria-mm study from the 61st ash annual meeting and exposition
Published 4 years ago • 26 plays • Length 0:59
Download video MP4
Download video MP3
Similar videos
-
1:35
joshua richter, md, regarding the phase 3 candor study in relapsed/refractory multiple myeloma
-
2:25
cevostamab in rrmm patients: camma 2 study results | joshua richter, md | eha 2024
-
1:23
noa biran, md, provides her impression of the phase 3 icaria-mm study
-
1:15
joshua richter, md, provides opinion on the role of bcma car-t cells in the management of mm
-
1:28
regeneron bispecific antibody targeting bcma update | joshua richter, md | ash 2021
-
3:11
bispecific antibodies | joshua richter, md | ash 2022
-
1:13
parameswaran hari, md, mrcp, offers his impression of the phase 3 icaria-mm trial from ash 2019
-
2:18
t cell re-direction therapy | joshua richter, md | eha 2022
-
1:31:54
cardiology 3 part 2
-
7:10
aortic stenosis – tavr (tavi) vs savr
-
16:43
transcatheter aortic valve replacement (tavr) vs. aortic valve replacement (avr)
-
1:25
safety and efficacy of linvoseltamab for patients with r/r multiple myeloma
-
1:36
dr. richter on the utility of isatuximab in relapsed/refractory myeloma
-
1:02
outcomes of patients with myeloma receiving fixed-duration cevostamab
-
2:40
ravi vij, in discussion with dr. joshua richter md, on managing the side effects of talquetamab
-
7:18
response rate on phase 1/2 trial regn5458 (bcmaxcd3 bispecific antibody) for rrmm patients
-
23:58
challenges &opportunities in rrmm management and role of isatuximab–dr.joshua richter(may26-27,2023)
-
2:18
preventing and monitoring infections with immune therapies | joshua richter, md | ims 2023
-
2:03
ash 2018: selexinor results in tow trials: storm and stomp
-
2:01
dr. joshua richter discusses multiple myeloma clinical trials
-
2:31
asco/eha 2024 myeloma highlights- imroz, dreamm-7, dreamm-8 | joshua richter, md | eha 2024
-
10:16
selinexor in multiple myeloma — dr. joshua richter | mcrt webcast july 11
Clip.africa.com - Privacy-policy